2 Top TSX Stocks Under $15 Per Share

Two outperforming TSX stocks trading for less than a cheap bottle of wine are excellent buying opportunities right now.

| More on:

The turbulence outside the country, particularly bank failures in the U.S., is shaking Canada’s main stock index. Nearly all primary sectors are under pressure, although six are in positive territory year to date. For individual stocks, beating the broader market TSX shows stability against strong headwinds.

Top TSX stocks Algonquin Power & Utilities (TSX:AQN) and Viemed Healthcare (TSX:VMD) continue outperforming with gains of 20.8% and 32.8%, respectively. Both are excellent buying opportunities, as they trade below $15 per share.

Long-term profitable growth

Algonquin Power & Utilities, a stalwart in global renewable energy, maintains a low-risk profile through its portfolio of long-term contracted wind, solar, and hydroelectric generating facilities. The $7.3 billion growth-oriented company also has a robust pipeline of renewable energy development projects.

As of December 31, 2022, Algonquin has over 600 megawatts of wind and solar projects in various stages of construction. Also, about 450 megawatts will come into service by year-end 2023. Management is focused on supporting Algonquin’s financial foundation and driving long-term profitable growth.

Its President and CEO, Arun Banskota, said the company closed 2022 on stable ground. Total revenue increased 22% to US$2.8 billion versus 2021, although net loss reached US$212 million. However, cash provided by operating activities jumped 293% year over year to US$619.1 million.  

At $10.65 per share, prospective investors can partake in the attractive 5.47% dividend. The yield is 40% lower than the previous quarter after decisive actions to strengthen Algonquin’s financial position. Besides the slash in the quarterly dividend, management will reduce capital intensity to address changing market conditions.

Algonquin desires to reduce its reliance on equity capital markets and doesn’t foresee new equity financings for the next two years. At year-end 2022, the available liquidity on the revolving and term credit facilities was approximately $2.3 billion. Bankota assures investors that the company will continue to execute its strategic priorities that well-prepare Algonquin for the future.

Darren Myers, Algonquin’s CFO, said, “Our regulated and renewables businesses are both well positioned to contribute to and benefit from the decarbonization transformation that is currently underway and which will only strengthen over the coming years.”

Growth opportunities

Healthcare was among the battered sectors in 2022 at the height of runaway inflation and rising interest rates. Fortunately, Viemed was an exception. At only $13.64 per share, the trailing one-year price return is 109.9%. Had you bought $6,000 worth of shares and held the stock in a Tax-Free Savings Account (TFSA), your money would be worth $13,011.13 today.

The $520.6 million company is an expert in home disease management. Respiratory therapists, licensed clinical social workers, clinicians, and healthcare administrators comprise Viemed’s team. They help patients manage serious respiratory conditions, including chronic obstructive pulmonary disease (COPD), neuromuscular diseases, and obstructive sleep apnea.

For the full year 2022, total revenue climbed 18.6% to US$138.8 million versus 2021. However, net income declined to US$6.2 million from US$9.1 million last year. Viemed’s CEO, Casey Hoyt, said, “The healthcare market and regulatory environment are stabilizing and we are at an inflection point of opportunity for both organic and inorganic growth.”

Cheap buys

Expect Algonquin and Viemed to capitalize on growth opportunities available to them. Soon, their share prices will be considerably higher than today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Viemed Healthcare. The Motley Fool has a disclosure policy.

More on Dividend Stocks

Dividend Stocks

The 2 Best Canadian Blue-Chip Stocks to Buy Now

Blue-chip stocks can be some of the best stocks to have in any portfolio. But when they're trending upwards, investors…

Read more »

Canadian dollars in a magnifying glass
Dividend Stocks

Here Are My Top 3 Dividend Stocks to Buy Now

These top dividends stocks have consistently paid and increased their dividends. Further, this trend will continue.

Read more »

dividends can compound over time
Dividend Stocks

Want a 7% Yield? The 3 TSX Stocks to Buy Today

These TSX stocks are offering high yields of over 7%, making them attractive for investors seeking steady passive income.

Read more »

how to save money
Dividend Stocks

The Smartest Dividend Stocks to Buy With $200 Right Now

These smartest dividend stocks can consistently pay and increase their dividends in the coming years, irrespective of the macro uncertainty.

Read more »

Electricity transmission towers with orange glowing wires against night sky
Dividend Stocks

3 Utility Stocks That Are Smart Buys for Canadians in November

These utility stocks benefit from regulated businesses and generate predictable cash flows that support higher dividend payouts.

Read more »

Start line on the highway
Dividend Stocks

Invest $10,000 in This Dividend Stock for $600 in Passive Income

Do you want to generate passive income? Forget the rental unit! This option will save you the mortgage yet still…

Read more »

Senior uses a laptop computer
Dividend Stocks

1 Reliable Dividend Stock for the Ultimate Retirement Income Stream

TD Bank (TSX:TD) shares are way too cheap with way too swollen a yield for retirees to pass up right…

Read more »

A worker drinks out of a mug in an office.
Dividend Stocks

Is Brookfield Infrastructure Partners a Buy for its 4.75% Yield?

Brookfield Infrastructure Partners (BIP) has a 4.75% dividend yield. Is it worth it?

Read more »